Your PSA of 0.21 ng/mL Meets the Definition of Biochemical Recurrence and Requires Confirmatory Testing Followed by Salvage Radiotherapy
You need a confirmatory PSA test, and if it remains ≥0.2 ng/mL, you should proceed with salvage radiotherapy as soon as possible, ideally while your PSA is still at this low level. 1
Immediate Next Steps
1. Obtain Confirmatory PSA Testing
- The American Urological Association and ASCO define biochemical recurrence as an initial PSA ≥0.2 ng/mL followed by a second confirmatory PSA ≥0.2 ng/mL 1
- Schedule this confirmatory test within 4-6 weeks
- Your current value of 0.21 ng/mL meets the threshold, but confirmation is required before proceeding with treatment
2. If Confirmed: Proceed with Restaging Evaluation
- Consider imaging to rule out distant metastatic disease before salvage therapy 1
- This may include advanced imaging (PSMA PET if available, or conventional CT/bone scan)
- The goal is to ensure you have no evidence of distant metastases, which would change the treatment approach
Why Salvage Radiotherapy Should Be Offered Now
The effectiveness of salvage radiotherapy is greatest when administered at lower PSA levels 1. Your PSA of 0.21 ng/mL is actually ideal timing for salvage treatment—waiting for it to rise higher significantly reduces the chance of cure.
Evidence Supporting Early Salvage Radiotherapy:
- Salvage radiotherapy reduces biochemical recurrence, local recurrence, and clinical progression 1
- Recent systematic review data (2021) shows that immediate radiotherapy in patients with persistent/early rising PSA improves survival outcomes 2
- Patients with PSA persistence or early recurrence have 5-year recurrence-free survival rates of only 21.5-67% without treatment, but salvage radiotherapy significantly improves these outcomes 2
What You Should Avoid
Do NOT adopt a "wait and see" approach without a clear plan:
- Your PSA pattern matters: Research shows that patients with "low detectable-unstable" PSA patterns (showing increases or PSA velocity ≥0.05 ng/mL per year) have only 37% 7-year biochemical recurrence-free survival compared to 94-95% for those with stable undetectable PSA 3
- While some patients with very low, stable PSA values (0.03-0.1 ng/mL) can be safely watched 3, 4, your value of 0.21 ng/mL is above this threshold and meets the definition of biochemical recurrence
Do NOT delay treatment waiting for symptoms:
- PSA recurrence precedes clinical metastases by years
- By the time symptoms develop, the cancer may no longer be curable with local therapy
Important Considerations for Your Discussion with Your Urologist/Radiation Oncologist
Factors That Influence Your Prognosis:
You should review your pathology report with your physician to assess:
- Surgical margin status (positive margins increase recurrence risk)
- Pathological stage (extraprostatic extension, seminal vesicle invasion)
- Gleason score/Grade Group from your prostatectomy specimen
- PSA velocity (how quickly your PSA is rising)
These factors help determine your absolute benefit from salvage radiotherapy and whether androgen deprivation therapy should be added 1, 2.
Potential Side Effects to Discuss:
Before proceeding, you should understand the possible urinary, bowel, and sexual adverse effects of radiotherapy, balanced against the benefits of controlling disease recurrence 1. Modern radiation techniques have reduced these risks, but they remain important considerations.
The Bottom Line Algorithm:
- Confirm PSA ≥0.2 ng/mL with repeat testing (4-6 weeks)
- If confirmed → Restaging imaging to rule out metastatic disease
- If no metastases → Salvage radiotherapy (± androgen deprivation therapy based on risk factors)
- Do not delay—treatment effectiveness decreases as PSA rises
Your PSA of 0.21 ng/mL is actually at an optimal level for salvage treatment if confirmed—this is when radiotherapy has the best chance of achieving long-term disease control.